Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16863673 | 0.78 | NOTUM (0.37) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3652642 | 0.57 | NPC1 (1.00) | RAB9ANPC1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL3619254 | 0.57 | ALDH1A1 (0.44) | RAB9ANPC1MAPK1KMT2AMEN1 | |
| Biphenyl SCHEMBL28890607 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL29560186 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL4002609 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30629023 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL2548048 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL1358618 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL164 | 0.57 | ALDH1A1 (1.00) | RAB9ANPC1MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | claimed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | claimed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | claimed |
| CN-1274670-C | Diaminopropionic acid derivatives | HOFFMANN LA ROCHE (CH) | 2006-09-13 | — | — | CN | claimed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | claimed |
| US-20040019039-A1 | Substituted piperazines and diazepanes | HIGH POINT PHARMACEUTICALS, LLC | 2004-01-29 | — | — | US | claimed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | claimed |
| US-4978362-A | Thermoplastic resin composition containing polyalkyleneoxy-substituted azo coloring agents having trifluoromethyl substituents | MILLIKEN RESEARCH CORPORATION (US) | 1990-12-18 | — | — | US | claimed |
| US-4751254-A | COLORING POLURETHANES USING POLYALKOXYTRIFLUOROANILINE COMPOUNDS | MILLIKEN RESEARCH CORPORATION (US) | 1988-06-14 | — | — | US | claimed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002050092-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002006270-A1 | NOVEL 6-HETEROARYLPHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | RAB9A 3209/4885NPC1 1743/4885MAPK1 3802/4885 |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | RAB9A 3209/4885NPC1 4189/4885MAPK1 61/4885 |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | RAB9A 2872/4885NPC1 3638/4885MAPK1 125/4885 |
| US-20040019039-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | RAB9A 3209/4885NPC1 1743/4885MAPK1 3802/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | RAB9A 2872/4885NPC1 3638/4885MAPK1 125/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | RAB9A 2872/4885NPC1 3638/4885MAPK1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.